Active Trials
AUR PRO
Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 046
Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, University of Chicago Medical Center, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 047
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Baylor, Dana-Farber/ Harvard Cancer Center, Duke, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, Vanderbilt University

TBCRC 058
A Study of Enzalutamide, Enzalutamide in Combination with Mifepristone, or Chemotherapy in People with Metastatic Breast Cancer

Dana-Farber/ Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill

TBCRC 059
ETHAN - Endocrine Therapy for Male Breast Cancer

Dana-Farber/ Harvard Cancer Center, Georgetown University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, University of North Carolina at Chapel Hill

TBCRC 060
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

University of North Carolina at Chapel Hill, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Washington University

TBCRC 061
Biomarker Analysis of Patients with Breast Cancer Receiving Immunotherapy

Baylor College of Medicine, Montefiore Medical Center, University of Chicago Medical Center, University of North Carolina at Chapel Hill, Vanderbilt University

TBCRC 062
STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Mayo Clinic Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, Vanderbilt University, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center 

Relevant Publications/Presentations: 2023 SABCS Poster

TBCRC 064
Treatment of ADC-Refractory Breast Cancer with Dato-DXd or T-DXd: TRADE DXd

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh, Vanderbilt University, Yale University

TBCRC 065
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy with Curative Intent in de novo HER2+ Metastatic Breast Cancer

Dana-Farber/ Harvard Cancer Center, MD Anderson Cancer Center, University of North Carolina at Chapel Hill, Yale University

TBCRC 066
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Baylor College of Medicine, Georgetown University, Johns Hopkins University, MD Anderson Cancer Center, Montefiore Medical Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Yale University